Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD, Astellas to Copromote Januvia-Suglat Combo
MSD and Astellas Pharma said on November 28 that they have sealed a definite accord for the copromotion of a fixed-dose combination paring Januvia (sitagliptin) and Suglat (ipragliflozin) - which are the first-in-class DPP-4 inhibitor and SGLT-2 inhibitor in Japan…
To read the full story
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…